GeneCode

Description

GeneCode develops small-molecule drugs that bind and activate GDNF receptors to protect and restore neurons, producing blood–brain-barrier-penetrant receptor agonists evaluated in preclinical models of Parkinson’s disease and other neurodegenerative conditions.

GeneCode is located in the Estonia ecosystem.

Related

• Confo TherapeuticsConfo Therapeutics develops GPCR-directed small-molecule and antibody therapies with proprietary technology that targets class A and B…
• BraineverBrainever develops hEN1 and hOTX2 homeoprotein drug candidates intended to limit neurodegenerative disease progression by preventing…
• ATXA TherapeuticsATXA Therapeutics develops selective small-molecule thromboxane receptor (TP) antagonists, including lead candidate NTP42, to treat…
• BioArcticBioArctic develops therapeutics and related technologies for neurodegenerative disorders, focusing on disease-modifying treatments and…
• BIMINI BiotechBIMINI Biotech develops first-in-class small-molecule therapeutics targeting the Wiskott–Aldrich Syndrome protein for oncology and…
• ImmunocoreImmunocore engineers ImmTAX T cell receptor–based therapeutics to activate or suppress immune responses, advancing bispecific TCR…
• OrganoTherapeuticsOrganoTherapeutics creates human iPSC-derived midbrain organoids, assembloids, and patient-specific Parkinson’s cell models, then provides…
• Breye TherapeuticsBreye Therapeutics develops orally administered ophthalmology drugs, including danegaptide and P2X7 receptor antagonists, to treat retinal…
• Herantis PharmaHerantis Pharma develops disease-modifying therapies designed to stop or reverse progression of neurodegenerative diseases, applying drug…